Orphan Therapeutics Acquires Full Rights To Terlipressin From PDL BioPharma
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will initiate a rolling NDA submission in Q2 2007 despite failure to meet novel primary endpoint, Orphan president tells “The Pink Sheet” DAILY.